| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acceptance and application of a broad population health perspective when evaluating vaccine
|
Persson, Ulf
|
|
|
40 |
24 |
p. 3395-3401
|
artikel
|
| 2 |
Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance
|
Nasreen, Sharifa
|
|
|
40 |
24 |
p. 3305-3312
|
artikel
|
| 3 |
Clinically proven specification setting for a meningococcal serogroup a conjugate vaccine
|
Onnis, Valeria
|
|
|
40 |
24 |
p. 3366-3371
|
artikel
|
| 4 |
COVID-19 and seasonal influenza: The potential 2021–22 “Twindemic”
|
Bellizzi, Saverio
|
|
|
40 |
24 |
p. 3286-3287
|
artikel
|
| 5 |
Differences in clinical outcomes of COVID-19 among vaccinated and unvaccinated kidney transplant recipients
|
Demir, Erol
|
|
|
40 |
24 |
p. 3313-3319
|
artikel
|
| 6 |
Domestic funding opportunities for Tanzania as five new Middle-Income countries brace for reduced Gavi support for immunization
|
Thomas Mori, Amani
|
|
|
40 |
24 |
p. 3278-3285
|
artikel
|
| 7 |
Dynamic changes in clinical characteristics and serotype distribution of invasive pneumococcal disease among adults in Japan after introduction of the pediatric 13-valent pneumococcal conjugate vaccine in 2013–2019
|
Tamura, Kosuke
|
|
|
40 |
24 |
p. 3338-3344
|
artikel
|
| 8 |
Editorial Board/Aims and Scope
|
|
|
|
40 |
24 |
p. IFC
|
artikel
|
| 9 |
Effectiveness of Covishield vaccine in preventing Covid-19 – A test-negative case-control study
|
Pramod, Stuti
|
|
|
40 |
24 |
p. 3294-3297
|
artikel
|
| 10 |
Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac
|
Nantanee, Rapisa
|
|
|
40 |
24 |
p. 3320-3329
|
artikel
|
| 11 |
Impact of prior infection and repeated vaccination on post-vaccination antibody titers of the influenza A(H1N1)pdm09 strain in Taiwan schoolchildren: Implications for public health
|
Liu, Wei
|
|
|
40 |
24 |
p. 3402-3411
|
artikel
|
| 12 |
Oral MucoRice-CTB vaccine is safe and immunogenic in healthy US adults
|
Yuki, Yoshikazu
|
|
|
40 |
24 |
p. 3372-3379
|
artikel
|
| 13 |
Post-authorization surveillance of adverse events following COVID-19 vaccines in pregnant persons in the vaccine adverse event reporting system (VAERS), December 2020 – October 2021
|
Moro, Pedro L.
|
|
|
40 |
24 |
p. 3389-3394
|
artikel
|
| 14 |
Predictors of hospitalisation and death due to SARS-CoV-2 infection in Finland: A population-based register study with implications to vaccinations
|
Salo, Heini
|
|
|
40 |
24 |
p. 3345-3355
|
artikel
|
| 15 |
Prevalence and factors of influenza vaccination during the COVID-19 pandemic among university students in China
|
Yu, Yanqiu
|
|
|
40 |
24 |
p. 3298-3304
|
artikel
|
| 16 |
Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial
|
Masuda, Taisei
|
|
|
40 |
24 |
p. 3380-3388
|
artikel
|
| 17 |
Self-reported COVID-19 vaccination acceptance and hesitancy among autistic adults
|
Shea, Lindsay L.
|
|
|
40 |
24 |
p. 3288-3293
|
artikel
|
| 18 |
TAK − 021, an inactivated Enterovirus 71 vaccine candidate, provides cross-protection against heterologous sub-genogroups in human scavenger receptor B2 transgenic mice
|
Tamura, Kanami
|
|
|
40 |
24 |
p. 3330-3337
|
artikel
|
| 19 |
Timely completion of childhood vaccination and its predictors in Burkina Faso
|
Koulidiati, Jean-Louis
|
|
|
40 |
24 |
p. 3356-3365
|
artikel
|
| 20 |
Using observational data to explore the hypothesis that a single dose of current HPV vaccines can provide durable protection
|
Velicer, Christine
|
|
|
40 |
24 |
p. 3275-3277
|
artikel
|
Tijdschrift beschrijving